Synchronous Small Cell and Adenocarcinoma of the Lung Integrating Morphology and Molecular Profiling: A Case Report
- 1Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, USA
- 2College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA
Abstract
Combined small cell lung carcinoma (SCLC) is not uncommon, though the combination with a second primary adenocarcinoma is less frequent. Molecular profiling can clarify clonal relationships and identify potentially actionable alterations, but interpretation requires careful integration with histologic and clinical findings. We report a 61-year-old woman with 2 synchronous right upper lobe tumors: a poorly differentiated combined SCLC with an adenocarcinoma component (cribriform 40%, acinar 30%, solid 30%) and a separate invasive adenocarcinoma (60% acinar, 40% lepidic), both staged pT1bN0M0. Core biopsy of the combined SCLC initially showed only adenocarcinoma morphology, highlighting the diagnostic limitations of undersampling in combined tumors. Molecular profiling revealed overlapping truncal alterations (TP53 C135Y, RB1 Q344, and KRAS G12C) at markedly discordant variant allele frequencies (VAF) of ∼46% in Tumor 1 versus ∼3% in Tumor 2, alongside a dominant KRAS G12V mutation unique to Tumor 2, a finding strongly associated with separate primary lung carcinomas rather than intrapulmonary metastasis. These molecular findings, interpreted in the context of field cancerization, favor independent primary tumors over clonal spread. The SCLC component dictated adjuvant cisplatin-etoposide regardless of the accompanying adenocarcinoma histology. This case report exemplifies the importance of integrated histologic and molecular evaluation, and the need to recognize potentially actionable mutations in combined SCLC. Comprehensive profiling not only clarifies clonal relationships and may guide therapeutic strategies, including in the context of recurrence or combined presentations.
Related
- Comprehensive Molecular Profiling for Precision Diagnostics: Integrating Genomic, Proteomic, and Epigenetic Landscapes in Human Pathology
- Endometrial Giant Cell Carcinoma Integrating Morphology, Immunophenotype, and Molecular Findings in a Misdiagnosed Case.
- Metabolic Profiling, Antioxidant Activity, and Mechanistic Insights of Chicory from Northern and Southern China: Integrating Metabolomics, Machine Learning, Molecular Docking, Molecular Dynamics Simulations, and In Vitro Assays
- Primary adrenal small cell neuroendocrine carcinoma in a patient with sarcoidosis and synchronous colon adenocarcinoma
- Synchronous lung adenocarcinoma and pulmonary carcinoid tumorlets in different lobes: a case report
BibTeX
@article{chang2026synchronous,
title = {{Synchronous Small Cell and Adenocarcinoma of the Lung Integrating Morphology and Molecular Profiling: A Case Report}},
author = {Robin Chang and Alejandro S. Mendoza and Swikrity U. Baskota},
journal = {International Journal of Surgical Pathology},
year = {2026},
month = jun,
doi = {10.1177/10668969261457876},
url = {https://doi.org/10.1177/10668969261457876},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Synchronous Small Cell and Adenocarcinoma of the Lung Integrating Morphology and Molecular Profiling: A Case Report
AU - Robin Chang
AU - Alejandro S. Mendoza
AU - Swikrity U. Baskota
PY - 2026
DA - 2026/06/30
JO - International Journal of Surgical Pathology
DO - 10.1177/10668969261457876
UR - https://doi.org/10.1177/10668969261457876
AB - Combined small cell lung carcinoma (SCLC) is not uncommon, though the combination with a second primary adenocarcinoma is less frequent. Molecular profiling can clarify clonal relationships and identify potentially actionable alterations, but interpretation requires careful integration with histologic and clinical findings. We report a 61-year-old woman with 2 synchronous right upper lobe tumors: a poorly differentiated combined SCLC with an adenocarcinoma component (cribriform 40%, acinar 30%, solid 30%) and a separate invasive adenocarcinoma (60% acinar, 40% lepidic), both staged pT1bN0M0. Core biopsy of the combined SCLC initially showed only adenocarcinoma morphology, highlighting the diagnostic limitations of undersampling in combined tumors. Molecular profiling revealed overlapping truncal alterations (TP53 C135Y, RB1 Q344, and KRAS G12C) at markedly discordant variant allele frequencies (VAF) of ∼46% in Tumor 1 versus ∼3% in Tumor 2, alongside a dominant KRAS G12V mutation unique to Tumor 2, a finding strongly associated with separate primary lung carcinomas rather than intrapulmonary metastasis. These molecular findings, interpreted in the context of field cancerization, favor independent primary tumors over clonal spread. The SCLC component dictated adjuvant cisplatin-etoposide regardless of the accompanying adenocarcinoma histology. This case report exemplifies the importance of integrated histologic and molecular evaluation, and the need to recognize potentially actionable mutations in combined SCLC. Comprehensive profiling not only clarifies clonal relationships and may guide therapeutic strategies, including in the context of recurrence or combined presentations.
SN - 1066-8969
SN - 1940-2465
ER -